Dominick Bosse, MD

Articles by Dominick Bosse, MD

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

October 9th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Latest Updated Articles

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC
October 9th 2017